Dublin, Nov. 03, 2020 (GLOBE NEWSWIRE) -- The "Chlamydia Infections - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
This guide provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 12 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.
Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chlamydia Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chlamydia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chlamydia Infections (Infectious Disease)
Key benefits:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chlamydia Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction
Chlamydia Infections - Overview
Chlamydia Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Chlamydia Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Chlamydia Infections - Companies Involved in Therapeutics Development
- Abera Bioscience AB
- Abivax SA
- BlueWillow Biologics Inc
- Erganeo
- Eurocine Vaccines AB
- Evofem Biosciences Inc
- Genetic Immunity Inc
- Lawrence Livermore National Laboratory
- Lead Discovery Center GmbH
- Merck & Co Inc
- Microbiotix Inc
- Prokarium Ltd
- QureTech Bio AB
- Traccine Pharmaceuticals
- Vault Pharma Inc
- Vaxine Pty Ltd
- Yaso Therapeutics Inc
Chlamydia Infections - Drug Profiles
PEG-2S - Drug Profile
Peptide to Inhibit CPAF for Chlamydia Infections - Drug Profile
PPCM - Drug Profile
Small Molecule for Chlamydia Infections - Drug Profile
Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile
Small Molecules to Inhibit 16S rRNA for Gonorrhea and Chlamydia Infections - Drug Profile
solithromycin - Drug Profile
VPI-201 - Drug Profile
Chlamydia Infections - Dormant Projects
Chlamydia Infections - Product Development Milestones
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/s6m3ya
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.